AR124034A1 - MODULADORES PPARg Y MÉTODOS DE USO - Google Patents
MODULADORES PPARg Y MÉTODOS DE USOInfo
- Publication number
- AR124034A1 AR124034A1 ARP210103111A ARP210103111A AR124034A1 AR 124034 A1 AR124034 A1 AR 124034A1 AR P210103111 A ARP210103111 A AR P210103111A AR P210103111 A ARP210103111 A AR P210103111A AR 124034 A1 AR124034 A1 AR 124034A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- hydrogen
- halogens
- alkyls
- formula
- Prior art date
Links
- 101150023417 PPARG gene Proteins 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical class *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: Ar¹ se elige entre los compuestos de fórmula (2) y (3) en donde Y¹ se elige entre N y C-X¹ en donde X¹ se elige entre hidrógeno, hidroxilo, halógenos y alquilos C₁₋₄; R³ se elige entre hidrógeno, alquilos opcionalmente sustituidos, aminas opcionalmente sustituidas, halógenos, ciano y alcoxis opcionalmente sustituidos; y R⁴ se elige entre hidrógeno y alquilos opcionalmente sustituidos; cada Y² se elige entre C-X² y N e Y³ es NH, o Y² es NH e Y³ es C-X², en donde X² se elige entre hidrógeno y halógenos; el Anillo A se elige entre anillos cíclicos saturados de 6 a 9 miembros opcionalmente sustituidos con al menos un sustituyente elegido entre halógenos, hidroxilo y alquilos opcionalmente sustituidos; R¹ se elige entre -(CHR⁵)ₖ-(CR⁶R⁷)ₙ-(O)ₘ-Anillo B, en donde k es 0 ó 1, n es 0 ó 1, m es 0 ó 1, R⁵ se elige entre hidrógeno y alquilos opcionalmente sustituidos, R⁶ se elige entre hidrógeno y halógenos, R⁷ se elige entre hidrógeno y halógenos, y el Anillo B se elige entre arilos opcionalmente sustituidos, heteroarilos opcionalmente sustituidos, cicloalquilos opcionalmente sustituidos, heterocicloalquilos opcionalmente sustituidos, cicloalquenilos opcionalmente sustituidos, y heterocicloalquenilos opcionalmente sustituidos; y R² se elige entre hidrógeno y alquilos opcionalmente sustituidos. Reivindicación 28: Una composición farmacéutica que comprende al menos una entidad elegida entre compuestos de fórmula (1) y sales farmacéuticamente aceptables de los mismos de acuerdo con una cualquiera de las reivindicaciones 1 a 27.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063111354P | 2020-11-09 | 2020-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124034A1 true AR124034A1 (es) | 2023-02-08 |
Family
ID=78820026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103111A AR124034A1 (es) | 2020-11-09 | 2021-11-09 | MODULADORES PPARg Y MÉTODOS DE USO |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230062861A1 (es) |
| EP (1) | EP4240736A1 (es) |
| JP (1) | JP2023549123A (es) |
| KR (1) | KR20230107291A (es) |
| CN (1) | CN116635380A (es) |
| AR (1) | AR124034A1 (es) |
| AU (1) | AU2021376300A1 (es) |
| CA (1) | CA3200524A1 (es) |
| IL (1) | IL302543A (es) |
| MX (1) | MX2023005371A (es) |
| TW (1) | TW202233598A (es) |
| WO (1) | WO2022099144A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023219879A1 (en) * | 2022-05-09 | 2023-11-16 | Eisai R&D Management Co., Ltd. | SOLID FORM OF PPAR-gamma MODULATORS AND METHODS OF USE |
| CN117800895A (zh) * | 2022-09-30 | 2024-04-02 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9562031B1 (en) | 2015-09-12 | 2017-02-07 | Sequoia Sciences, Inc. | Phenethyldihydrobenzodioxolones and methods of use |
| US10525048B2 (en) * | 2015-09-18 | 2020-01-07 | Memorial Sloan Kettering Cancer Center | Methods and compositions of inhibiting DCN1-UBC12 interaction |
| EP3498694A1 (en) * | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
-
2021
- 2021-11-08 WO PCT/US2021/058473 patent/WO2022099144A1/en active Application Filing
- 2021-11-08 EP EP21816611.4A patent/EP4240736A1/en active Pending
- 2021-11-08 JP JP2023527349A patent/JP2023549123A/ja active Pending
- 2021-11-08 KR KR1020237019226A patent/KR20230107291A/ko unknown
- 2021-11-08 CA CA3200524A patent/CA3200524A1/en active Pending
- 2021-11-08 MX MX2023005371A patent/MX2023005371A/es unknown
- 2021-11-08 IL IL302543A patent/IL302543A/en unknown
- 2021-11-08 CN CN202180089308.6A patent/CN116635380A/zh active Pending
- 2021-11-08 US US17/521,666 patent/US20230062861A1/en active Pending
- 2021-11-08 AU AU2021376300A patent/AU2021376300A1/en active Pending
- 2021-11-09 AR ARP210103111A patent/AR124034A1/es unknown
- 2021-11-09 TW TW110141725A patent/TW202233598A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL302543A (en) | 2023-07-01 |
| CA3200524A1 (en) | 2022-05-12 |
| AU2021376300A9 (en) | 2024-10-10 |
| WO2022099144A1 (en) | 2022-05-12 |
| US20230062861A1 (en) | 2023-03-02 |
| JP2023549123A (ja) | 2023-11-22 |
| AU2021376300A1 (en) | 2023-06-22 |
| EP4240736A1 (en) | 2023-09-13 |
| KR20230107291A (ko) | 2023-07-14 |
| TW202233598A (zh) | 2022-09-01 |
| CN116635380A (zh) | 2023-08-22 |
| MX2023005371A (es) | 2023-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124034A1 (es) | MODULADORES PPARg Y MÉTODOS DE USO | |
| AR110346A1 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| AR114950A1 (es) | Compuestos de benzamida | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR108130A1 (es) | Derivados de pirazolopirimidina | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| AR058198A1 (es) | Derivados de morfolina y composiciones farmaceuticas | |
| CO5690588A2 (es) | Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| AR105911A1 (es) | Inhibidores de hdac8 bicíclicos fusionados [6,6] | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR104415A1 (es) | Compuestos antiestrogénicos derivados de cromeno | |
| AR087792A1 (es) | Compuestos heterociclicos tetraciclicos y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR111874A1 (es) | Derivados de pirimidina | |
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
| AR126914A1 (es) | Inhibidores de ras novedosos |